Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-64417184 acid-reducing agent drug-drug interaction crossover study
NL-OMON50152Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of JNJ-64417184 in respiratory syncytial virus disease (RSV) (3 arms), sponsored by Janssen Pharmaceutical. Started Jul 2020; status: active, not recruiting.
02
Drugs
JNJ-64417184
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON50152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50152.